Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.

BACKGROUND  In the United States, >40% of people infected with human immunodeficiency virus (HIV) smoke cigarettes. METHODS  We used a computer simulation of HIV disease and treatment to project the life expectancy of HIV-infected persons, based on smoking status. We used age- and sex-specific data on mortality, stratified by smoking status. The ratio of the non-AIDS-related mortality risk for current smokers versus that for never smokers was 2.8, and the ratio for former smokers versus never smokers was 1.0-1.8, depending on cessation age. Projected survival was based on smoking status, sex, and initial age. We also estimated the total potential life-years gained if a proportion of the approximately 248 000 HIV-infected US smokers quit smoking. RESULTS  Men and women entering HIV care at age 40 years (mean CD4+ T-cell count, 360 cells/µL) who continued to smoke lost 6.7 years and 6.3 years of life expectancy, respectively, compared with never smokers; those who quit smoking upon entering care regained 5.7 years and 4.6 years, respectively. Factors associated with greater benefits from smoking cessation included younger age, higher initial CD4+ T-cell count, and complete adherence to antiretroviral therapy. Smoking cessation by 10%-25% of HIV-infected smokers could save approximately 106 000-265 000 years of life. CONCLUSIONS  HIV-infected US smokers aged 40 years lose >6 years of life expectancy from smoking, possibly outweighing the loss from HIV infection itself. Smoking cessation should become a priority in HIV treatment programs.

[1]  Brian A. King,et al.  Current Cigarette Smoking Among Adults — United States, 2016 , 2015, MMWR. Morbidity and mortality weekly report.

[2]  D. Klein,et al.  Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care , 2016, Journal of acquired immune deficiency syndromes.

[3]  C. Gibert,et al.  Contemplation of Smoking Cessation and Quit Attempts in Human Immunodeficiency Virus–Infected and Uninfected Veterans , 2016, Substance abuse.

[4]  A. Siu Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. , 2015, Annals of internal medicine.

[5]  L. Pacek,et al.  Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV , 2015, Current HIV/AIDS Reports.

[6]  Milton C Weinstein,et al.  Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. , 2015, JAMA.

[7]  B. Nordestgaard,et al.  Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Weinstein,et al.  The clinical role and cost-effectiveness of long-acting antiretroviral therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Brennan,et al.  Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus , 2015, Annals of Internal Medicine.

[10]  J. Skarbinski,et al.  Cigarette Smoking Prevalence Among Adults With HIV Compared With the General Adult Population in the United States , 2015, Annals of Internal Medicine.

[11]  J. Sterne,et al.  Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America , 2015, AIDS.

[12]  Brian A. King,et al.  Current cigarette smoking among adults - United States, 2005-2014. , 2015, MMWR. Morbidity and mortality weekly report.

[13]  Brian A. King,et al.  Current Cigarette Smoking Among Adults — United States, 2005–2013 , 2014, MMWR. Morbidity and mortality weekly report.

[14]  S. Bojesen,et al.  Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV , 2014, AIDS.

[15]  Mardge H. Cohen,et al.  Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals , 2014, AIDS.

[16]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[17]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[18]  J. Gatell,et al.  Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[19]  Clare Brennan,et al.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.

[20]  B. Nordestgaard,et al.  Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Prabhat Jha,et al.  21st-century hazards of smoking and benefits of cessation in the United States. , 2013, The New England journal of medicine.

[22]  Michael J Thun,et al.  50-year trends in smoking-related mortality in the United States. , 2013, The New England journal of medicine.

[23]  M. Weinstein,et al.  Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States , 2013, Annals of Internal Medicine.

[24]  Richard D Moore,et al.  Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care , 2012, Journal of acquired immune deficiency syndromes.

[25]  A. Mocroft,et al.  All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. , 2012, International journal of epidemiology.

[26]  C. Larsen,et al.  Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study , 2012, AIDS.

[27]  P. Sax,et al.  Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States , 2012, PloS one.

[28]  T. Gilmer,et al.  Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDS , 2011, Journal of managed care pharmacy : JMCP.

[29]  A. Justice,et al.  HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. , 2011, American journal of respiratory and critical care medicine.

[30]  A. Lifson,et al.  Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. , 2010, American journal of public health.

[31]  Richard D Moore,et al.  Late presentation for human immunodeficiency virus care in the United States and Canada. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Buskin,et al.  Cigarette Smoking and Mortality Among HIV-Infected Individuals in Seattle, Washington (1996–2008) , 2010, AIDS and Behavior.

[33]  Richard D Moore,et al.  Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Deepak L. Bhatt,et al.  Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  S. Crystal,et al.  Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. , 2009, AIDS education and prevention : official publication of the International Society for AIDS Education.

[36]  M. Roberts,et al.  Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Ragnaud,et al.  Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. , 2007, AIDS patient care and STDs.

[38]  J. Benner,et al.  Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus , 2006, Medical care.

[39]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[40]  J. Stockman,et al.  Mortality in Relation to Smoking: 50 Years' Observations on Male British Doctors , 2006 .

[41]  Milton C Weinstein,et al.  Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.

[42]  M. Weinstein,et al.  HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[44]  S. Self,et al.  Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. , 2001, American journal of epidemiology.

[45]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[46]  D. Coyle,et al.  Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[47]  J. Manson,et al.  Smoking Cessation and Time Course of Decreased Risks of Coronary Heart Disease in Middle-Aged Women , 1994 .